Crossject Société Anonyme (ALCJ.PA)
4.67 €
+0.04 (+0.97%)
Rating:
Recommendation:
-
| Symbol | ALCJ.PA |
|---|---|
| Price | 4.67 € |
| Beta | 1.053 |
| Volume Avg. | 0.04M |
| Market Cap | 170.983M |
| Shares () | - |
| 52 Week Range | 3.195-5.0 |
| 1y Target Est | - |
| DCF Unlevered | ALCJ.PA DCF -> | |
|---|---|---|
| DCF Levered | ALCJ.PA LDCF -> | |
| ROE | 798.35% | Strong Buy |
| ROA | -33.95% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 591.59% | Strong Buy |
| P/E | -12.97 | Strong Sell |
| P/B | 63.49 | Strong Buy |
About
Download (Excel)Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.